What is the optimal isodose line for stereotactic radiotherapy for single brain metastases using HyperArc?

Tomohiro Sagawa,Toshiki Ikawa,Shingo Ohira,Naoyuki Kanayama,Yoshihiro Ueda,Shoki Inui,Masayoshi Miyazaki,Koji Konishi
DOI: https://doi.org/10.1002/acm2.14408
2024-06-13
Journal of Applied Clinical Medical Physics
Abstract:Purpose The study aimed to investigate the optimal isodose line (IDL) in linear accelerator‐based stereotactic radiotherapy for single brain metastasis, using HyperArc. We compared the dosimetric parameters for target and normal brain tissue among six plans with different IDLs. Methods This study included 30 patients with single brain metastasis. We retrospectively generated six plans for each tumor with different IDLs (80%, 70%, 60%, 50%, 40%, and 33%) using HyperArc. All treatment plans were normalized to the prescription dose of 35 Gy in five fractions which was covered by 95% of the planning target volume (PTV), defined by adding a 1.0 mm margin to the gross tumor volume (GTV). The dosimetric parameters were compared among the six plans. Results For GTV > 0.1 cm3, the ratio of brain–GTV volumes receiving 25 Gy to PTV (V25Gy/PTV) was significantly lower at IDL 40%–70% than at IDL 80% and 33% (p 0.1 cm3. These lower IDLs could increase D99% and D80% of GTV while lowering V25Gy of normal brain tissue, which may help reduce the risk of radiation necrosis and improve local control.
radiology, nuclear medicine & medical imaging
What problem does this paper attempt to address?